

Late-Stage *ortho*-C–H Alkenylation of 2-Arylindazoles in Aqueous Medium by Manganese(I)-Catalysis

Krishna Kanta Das, Asim Kumar Ghosh and Alakananda Hajra*

Department of Chemistry, Visva-Bharati (A Central University), Santiniketan 731235, India;
Tel./Fax: +913463 261526; E-mail: alakananda.hajra@visva-bharati.ac.in

Table of Contents


1.	General Information	S2
2.	Experimental procedures	S2-S7
3.	Mechanistic investigations	S7-S10
4.	Characterization data for the synthesized products	S10-S22
5.	References	S23
6.	NMR spectra for the synthesized products	S24-S130

1. General information:


All reagents were purchased from commercial sources and used without further purification. ^1H NMR spectra were determined on 400 MHz spectrometer as solutions in CDCl_3 . Chemical shifts are expressed in parts per million (δ) and the signals were reported as s (singlet), d (doublet), t (triplet), m (multiplate) and coupling constants (J) were given in Hz. $^{13}\text{C}\{^1\text{H}\}$ NMR spectra were recorded at 100 MHz in CDCl_3 and $\text{DMSO}-d_6$ solution. NMR data are reported relative to residual CHCl_3 (^1H , $\delta = 7.26$ ppm) and CDCl_3 (^{13}C , $\delta = 77.16$ ppm) or $\text{DMSO}-d_6$ (^1H , $\delta = 2.50$ ppm). TLC was done on silica gel coated glass slide. All 2-arylindazoles¹ were prepared by the reported methods. All solvents were dried and distilled before use. Commercially available solvents were freshly distilled before the reaction. All reactions involving moisture sensitive reactants were executed using oven dried glassware. Melting points (M.p.) were determined after recrystallization of solid compounds from a solution of dichloromethane/petroleum ether (1:3).

2. Experimental procedures:

2.1. Typical procedures for the synthesis of prop-2-yn-1-yl benzoate derivatives (2):²




A mixture of 4-methylbenzoic acid (10.0 mmol, 1.36 g), 3-bromoprop-1-yne (12.0 mmol, 1.45 g) and anhydrous K_2CO_3 (4.14 g, 3.0 equiv.) in acetone (15 mL) was stirred for 12 h in reflux. When the reaction was complete (as monitored by TLC), the solvent was evaporated under reduced pressure. The residue was purified by column chromatography over silica gel with mixtures of PE/AcOEt to give the desired product 2.




Prop-2-yn-1-yl 4-methylbenzoate (2a): Yellow gummy mass (91%, 1.5 g); $R_f = 0.50$ (PE/EA = 96 : 4); ^1H NMR (400 MHz, CDCl_3): δ 7.89 (d, $J = 8.0$ Hz, 2H), 7.17 (d, $J = 8.0$ Hz, 2H), 4.83 (d, $J = 2.4$ Hz, 2H), 2.44 (t, $J = 2.8$ Hz, 1H), 2.34 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz,


CDCl_3): δ 165.9, 144.2, 129.9, 129.2, 126.7, 77.9, 75.0, 52.3, 21.8; Anal. Calcd for $\text{C}_{11}\text{H}_{10}\text{O}_2$: C, 75.84; H, 5.79%; Found: C, 75.97; H, 5.75%.




Prop-2-yn-1-yl 4-chlorobenzoate (2b): Yellow gummy mass (89%, 1.7 g); $R_f = 0.50$ (PE/ EA = 97 : 3); ^1H NMR (400 MHz, CDCl_3): δ 7.98 (d, $J = 8.4$ Hz, 2H), 7.40 (d, $J = 8.4$ Hz, 2H), 4.90 (d, $J = 2.4$ Hz, 2H), 2.53 (t, $J = 2.4$ Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.0, 139.9, 131.2, 128.9, 127.8, 77.5, 75.3, 52.7; Anal. Calcd for $\text{C}_{10}\text{H}_7\text{ClO}_2$: C, 61.72; H, 3.63%; Found: C, 61.57; H, 3.68%.




Prop-2-yn-1-yl 4-cyanobenzoate (2c): Yellow solid (82%, 1.5 g); $R_f = 0.50$ (PE/ EA = 95 : 5); M.P. 85–86 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.17 (d, $J = 8.4$ Hz, 2H), 7.76 (d, $J = 8.4$ Hz, 2H), 4.95 (d, $J = 2.4$ Hz, 2H), 2.55 (t, $J = 2.4$ Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 164.3, 133.2, 132.4, 130.4, 118.0, 116.8, 75.7, 53.3; Anal. Calcd for $\text{C}_{11}\text{H}_7\text{NO}_2$: C, 71.35; H, 3.81; N, 7.56%; Found: C, 71.49; H, 3.78; N, 7.49%.




Prop-2-yn-1-yl nicotinate (2d): Yellow gummy mass (84%, 1.3 g); $R_f = 0.45$ (PE/ EA = 92 : 8); ^1H NMR (400 MHz, CDCl_3): δ 9.15 (s, 1H), 8.71–8.69 (m, 1H), 8.25–8.21 (m, 1H), 7.35–7.31 (m, 1H), 4.92–4.87 (m, 2H), 2.53–2.52 (m, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 164.4, 153.6, 150.8, 137.2, 125.2, 123.3, 75.5, 52.7; Anal. Calcd for $\text{C}_9\text{H}_7\text{NO}_2$: C, 67.08; H, 4.38; N, 8.69%; Found: C, 66.91; H, 4.40; N, 8.81%.



Prop-2-yn-1-yl pivalate (2e): Yellow liquid (94%, 1.3 g); $R_f = 0.55$ (PE/ EA = 98 : 2); ^1H NMR (400 MHz, CDCl_3): δ 4.62 (d, $J = 2.4$ Hz, 2H), 2.42 (t, $J = 2.4$ Hz, 1H), 1.18 (s, 9H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 177.7, 78.0, 74.6, 52.0, 38.7, 27.1; Anal. Calcd for $\text{C}_8\text{H}_{12}\text{O}_2$: C, 68.55; H, 8.63%; Found: C, 68.75; H, 8.59%.




Prop-2-yn-1-yl cyclohexanecarboxylate (2f): Yellow liquid (92%, 1.5 g); $R_f = 0.55$ (PE/ EA = 97 : 3); ^1H NMR (400 MHz, CDCl_3): δ 4.63 (d, $J = 2.4$ Hz, 2H), 2.44 (t, $J = 2.8$ Hz, 1H), 2.35–2.28 (m, 1H), 1.90–1.87 (m, 2H), 1.74–1.70 (m, 2H), 1.62–1.59 (m, 1H), 1.46–1.37 (m, 2H), 1.30–1.16 (m, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 175.2, 77.9, 74.7, 51.7, 42.9, 28.9, 25.7, 25.4; Anal. Calcd for $\text{C}_{10}\text{H}_{14}\text{O}_2$: C, 72.26; H, 8.49%; Found: C, 72.08; H, 8.53%.




Prop-2-yn-1-yl (3r,5r,7r)-adamantane-1-carboxylate (2g): Yellow liquid (98%, 2.1 g); $R_f = 0.50$ (PE/ EA = 96 : 4); ^1H NMR (400 MHz, CDCl_3): δ 4.61 (d, $J = 2.4$ Hz, 2H), 2.43–2.42 (m, 1H), 1.98 (s, 3H), 1.87 (s, 6H), 1.68 (t, $J = 14.8$ Hz, 6H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 176.8, 78.1, 74.5, 51.7, 40.7, 38.6, 36.4, 27.9; Anal. Calcd for $\text{C}_{14}\text{H}_{18}\text{O}_2$: C, 77.03; H, 8.31%; Found: C, 77.19; H, 8.28%.


2.2. Typical procedures for the synthesis of 1-methyl-4-(prop-2-yn-1-yloxy)benzene (2):³




A mixture of *p*-cresol (10.0 mmol, 1.08 g), 3-bromoprop-1-yn-1-yl bromide (12.0 mmol, 1.45 g) and anhydrous K_2CO_3 (4.14 g, 3.0 equiv.) in DMF (15 mL) was stirred for 12 h at room temperature. After completion of the reaction (TLC), the reaction mixture was extracted with DCM. The organic phase was dried over anhydrous Na_2SO_4 . The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate as an eluting solvent to afford the pure product **2**.



1-methyl-4-(prop-2-yn-1-yloxy)benzene (2i): Yellow gummy mass (96%, 1.4 g); $R_f = 0.45$ (PE/ EA = 95 : 5); ^1H NMR (400 MHz, CDCl_3): δ 7.14 (d, $J = 8.4$ Hz, 2H), 6.93–6.89 (m, 2H), 4.68 (d, $J = 2.4$ Hz, 2H), 2.54 (t, $J = 2.4$ Hz, 1H), 2.33 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 155.4, 130.9, 130.0, 114.7, 78.8, 75.4, 55.8, 20.5; Anal. Calcd for $\text{C}_{10}\text{H}_{10}\text{O}$: C, 82.16; H, 6.90%; Found: C, 81.95; H, 6.95%.




4-methyl-N-(prop-2-yn-1-yl)aniline (2j): Brown solid (91%, 1.3 g); $R_f = 0.50$ (PE/ EA = 95 : 5); M.P. 46-47 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.10-7.07 (m, 2H), 6.68-6.65 (m, 2H), 3.94 (s, 2H), 3.78 (s, 1H), 2.31 (s, 3H), 2.25 (t, $J = 2.0$ Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 144.6, 129.7, 127.9, 113.8, 81.3, 71.2, 33.9, 20.4; Anal. Calcd for $\text{C}_{10}\text{H}_{11}\text{N}$: C, 82.72; H, 7.64; N, 9.65%; Found: C, 82.85; H, 7.62, N, 9.56%.




Prop-2-yn-1-yl(p-tolyl)sulfane (2k): Yellow gummy mass (86%, 1.3 g); $R_f = 0.50$ (PE/ EA = 97 : 3); ^1H NMR (400 MHz, CDCl_3): δ 7.39 (d, $J = 8.0$ Hz, 2H), 7.15 (d, $J = 8.0$ Hz, 2H), 3.56 (d, $J = 2.8$ Hz, 2H), 2.35 (s, 3H), 2.24 (t, $J = 2.4$ Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 137.3, 131.1, 131.0, 129.8, 80.1, 71.5, 23.2, 21.1; Anal. Calcd for $\text{C}_{10}\text{H}_{10}\text{S}$: C, 74.03; H, 6.21%; Found: C, 73.88; H, 6.23%.

2.3. Typical procedures for the synthesis of (2):⁴




A mixture of phenylalanine (10.0 mmol, 1.65 g) and NaHCO_3 (3.0 equiv., 2.52 g) in THF and H_2O (1:1 v/v) was stirred for 15 min at room temperature. After that, Boc_2O (12.0 mmol, 2.62 g) was added to the reaction mixture at 0 °C for 30 min. Then the reaction was stirred at room temperature for overnight. When the reaction was complete (as monitored by TLC), 2.0 (M) HCl was added drop wise to maintain the pH = 2-3. The reaction mixture was extracted with EtOAc. The organic phase was dried over anhydrous Na_2SO_4 . The crude residue was obtained after evaporating the solvent in vacuum. The resulting crude material was used for the next step without further purification. Next step was similar to the procedure 2.1.




Prop-2-yn-1-yl (tert-butoxycarbonyl)-L-phenylalaninate (2l): Yellow liquid (82%, 2.4 g); $R_f = 0.50$ (PE/ EA = 90 : 10); ^1H NMR (400 MHz, CDCl_3): δ 7.32-7.23 (m, 3H), 7.21-7.16 (m, 2H), 5.04 (d, $J = 6.0$ Hz, 1H), 4.78-4.56 (m, 3H), 3.18-3.06 (m, 2H), 2.53 (t, $J = 2.4$ Hz, 1H),

1.42 (s, 9H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 171.1, 155.0, 135.7, 129.4, 128.5, 127.1, 80.0, 77.0, 75.5, 54.3, 52.6, 38.0, 28.2; Anal. Calcd for $\text{C}_{17}\text{H}_{21}\text{NO}_4$: C, 67.31; H, 6.98; N, 4.62%; Found: C, 67.47; H, 7.01; N, 4.49%.




Prop-2-yn-1-yl (tert-butoxycarbonyl)-L-valinate (2m): Yellow liquid (67%, 1.7 g); $R_f = 0.50$ (PE/ EA = 94 : 6); ^1H NMR (400 MHz, CDCl_3): δ 5.04 (d, $J = 8.8$ Hz, 1H), 4.72-4.56 (m, 2H), 2.44 (s, 1H), 2.11-2.04 (m, 1H), 1.40-1.39 (m, 1H), 1.34 (s, 9H), 0.90-0.81 (m, 6H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 171.6, 155.5, 79.7, 75.3, 58.3, 52.3, 31.2, 28.2, 18.9, 17.4; Anal. Calcd for $\text{C}_{13}\text{H}_{21}\text{NO}_4$: C, 61.16; H, 8.29; N, 5.49%; Found: C, 61.04; H, 8.27; N, 5.57%.




1-(tert-butyl) 2-(prop-2-yn-1-yl) (S)-indoline-1,2-dicarboxylate (2n): Yellow liquid (72%, 2.1 g); $R_f = 0.45$ (PE/ EA = 90 : 10); ^1H NMR (400 MHz, CDCl_3): δ 7.89 (d, $J = 6.8$ Hz, 1H), 7.18 (t, $J = 7.6$ Hz, 1H), 7.09 (d, $J = 7.2$ Hz, 1H), 6.95-6.91 (m, 1H), 4.88 (d, $J = 8.4$ Hz, 1H), 4.78-4.67 (m, 2H), 3.53-3.46 (m, 1H), 3.13-3.08 (m, 1H), 2.49 (s, 1H), 1.50 (s, 9H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 171.1, 151.4, 142.4, 127.9, 127.6, 124.8, 124.3, 122.6, 114.6, 81.5, 75.4, 60.1, 52.6, 32.5, 28.2; Anal. Calcd for $\text{C}_{17}\text{H}_{19}\text{NO}_4$: C, 67.76; H, 6.36; N, 4.65%; Found: C, 67.93; H, 6.32; N, 4.59%.

2.4. Typical experimental procedure for 3aa:



A mixture of 2-phenyl-2*H*-indazole (**1a**) (0.25 mmol, 48.5 mg), $\text{MnBr}(\text{CO})_5$ (10 mol%, 6.8 mg), and NaOAc (20 mol%, 4.1 mg) was taken in an oven dried screw-capped reaction tube. Then the reaction vessel was evacuated and filled with nitrogen for three times. Then prop-2-yn-1-yl 4-methylbenzoate (**2a**) (0.3 mmol, 52.2 mg) and H_2O (2 mL) was added to the mixture and the resultant mixture was stirred at 100 °C in a preheated oil bath for 8 h. After completion of the reaction (TLC), the reaction was cooled to room temperature and extracted with ethyl acetate. The organic phase was dried over anhydrous Na_2SO_4 . The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate.


2.5. Synthesis of 3aa on 5 mmol scale:



A mixture of 2-phenyl-2*H*-indazole (**1a**) (5.0 mmol, 0.97 g), MnBr(CO)₅ (10 mol%, 137.0 mg), and NaOAc (20 mol%, 83.0 mg) was taken in an oven dried screw-capped reaction tube. Then the reaction vessel was evacuated and filled with nitrogen for three times. Then prop-2-yn-1-yl 4-methylbenzoate (**2a**) (6.0 mmol, 1.04 g) and H₂O (25 mL) was added to the mixture and the resultant mixture was stirred at 100 °C in a preheated oil bath for 8 h. After completion of the reaction (TLC), the reaction was cooled to room temperature and extracted with ethyl acetate. The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate (85:15) as an eluting solvent to afford the pure product **3aa** (1.4 g, 79%) as a Yellow gummy mass.


3. Mechanistic investigations:⁵

3.1. Preparation of 2-(4-methylphenyl-2,6-*d*₂)-2*H*-indazole (**1b-d**₂):




A mixture of 2-(*p*-tolyl)-2*H*-indazole (0.25 mmol, 52 mg) (**1b**), [MnBr(CO)₅] (10 mol %, 6.8 mg), and NaOAc (20 mol%, 4.1 mg) was taken in an oven dried screw-capped reaction tube. Then 1,4-dioxane (2 mL) was added to the mixture and stirred for 5 min at room temperature under open atmosphere. After that, D₂O (1 mL) was added, and the resultant mixture was stirred at 100 °C for 8 h. Then, the reaction was cooled to room temperature and extracted with dichloromethane. The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate (85:15) as an eluting solvent to afford the pure product **1b-d**₂ as a white solid. The deuterium incorporation was determined using 400 MHz ¹H NMR as 100%.

¹H NMR (400 MHz, CDCl₃) spectrum of 1b-d₂




3.2. Intermolecular kinetic isotope effect study:




Ethynylbenzene (**2r**) (0.24 mmol, 24.5 mg) was reacted with 2-(*p*-tolyl)-2*H*-indazole (**1b**) (0.1 mmol, 20.8 mg) and 2-(4-methylphenyl-2,6-*d*₂)-2*H*-indazole (**1b-d**₂) (0.1 mmol, 21.0 mg) for 25 min under standard reaction condition. The resulting solution was then diluted with dichloromethane (3 x 10 mL) and washed with brine (2 x 5 mL) and water (5 mL). The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate (95:5). The intermolecular *k*_H/*k*_D was found to be **1.0** after 25 min at ~29% conversion, based on 400 MHz ¹H NMR of the product **3br** and **3br-d**₁.

¹H NMR (400 MHz, CDCl₃) spectrum of 3br and 3br-*d*₁



3.3. Parallel kinetic isotope effect study:



In a set of two experiments: in first set, ethynylbenzene (**2r**) (0.12 mmol, 12.2 mg) was reacted with 2-(*p*-tolyl)-2*H*-indazole (**1b**) (0.1 mmol, 20.8 mg) under standard reaction conditions. Whereas in another set, 2-(4-methylphenyl-2,6-*d*₂)-2*H*-indazole (**1b-d₂**) (0.1 mmol, 21.0 mg) was used instead of **1b** in the reaction with ethynylbenzene (**2r**) under the standard reaction conditions. The reactions were quenched at 25 min, 50 min, 75 min, 100 min respectively. The resulting solution was then diluted with dichloromethane (3 x 10 mL) and washed with brine (2 x 5 mL) and water (5 mL). The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography. The calculated k_H/k_D value was found to be 1.1.

t/min	25	50	75	100
yield				

3br	15.5%	23.6%	28.6%	32.1%
3br-d₁	14.1%	21.4%	26.2%	29.1%






Figure S1. The reaction rate of 1b and 1b-d₁


4. Characterization data for the synthesized products:




(E)-3-(2-(2H-indazol-2-yl)phenyl)allyl 4-methylbenzoate (3aa): Yellow gummy mass (91%, 83.8 mg); R_f = 0.50 (PE/ EA = 85 : 15); ¹H NMR (400 MHz, CDCl₃): δ 8.14 (s, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.74-7.71 (m, 1H), 7.53-7.40 (m, 3H), 7.38-7.34 (m, 1H), 7.17-7.12 (m, 3H), 6.55 (d, J = 16.0 Hz, 1H), 6.45-6.38 (m, 1H), 4.86 (d, J = 5.6 Hz, 2H), 2.38 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 166.3, 149.5, 143.7, 139.0, 132.3, 129.6, 129.3, 129.1, 128.6, 127.8, 127.2, 126.97, 126.94, 126.8, 126.7, 125.4, 122.4, 122.1, 120.5, 118.0, 64.8, 21.7; Anal. Calcd for C₂₄H₂₀N₂O₂: C, 78.24; H, 5.47; N, 7.60%; Found: C, 78.39; H, 5.50; N, 7.70%.




(E)-3-(2-(2H-indazol-2-yl)phenyl)allyl 4-chlorobenzoate (3ab): White solid (94%, 91.3 mg); R_f = 0.50 (PE/ EA = 85 : 15); M.P. 81-82 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.09 (s, 1H), 7.80-7.75 (m, 3H), 7.71-7.67 (m, 2H), 7.49-7.32 (m, 4H), 7.26-7.24 (m, 2H), 7.15-7.12 (m, 1H), 6.50 (d, J = 16.0 Hz, 1H), 6.40-6.33 (m, 1H), 4.85-4.83 (m, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 165.2, 149.5, 139.4, 138.9, 132.2, 130.9, 129.3, 128.7, 128.6, 128.3, 127.7, 126.9, 126.7, 126.6, 126.3, 125.3, 122.4, 122.0, 120.4, 117.9, 64.9; Anal. Calcd for C₂₃H₁₇ClN₂O₂: C, 71.04; H, 4.41; N, 7.20%; Found: C, 71.22; H, 4.39; N, 7.12%.



(E)-3-(2-(2H-indazol-2-yl)phenyl)allyl 4-cyanobenzoate (3ac): Yellow solid (90%, 85.3 mg); R_f = 0.50 (PE/ EA = 80 : 20); M.P. 107-108 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.11 (s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.82-7.69 (m, 3H), 7.58 (d, J = 8.4 Hz, 2H), 7.50-7.46 (m, 2H), 7.44-7.42 (m, 1H), 7.38-7.34 (m, 1H), 7.18-7.14 (m, 1H), 6.51 (d, J = 16.0 Hz, 1H), 6.42-6.35 (m, 1H), 4.91-4.89 (m, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 164.5, 149.5, 139.0, 133.6, 132.2, 132.1, 130.0, 129.4, 128.7, 127.8, 126.9, 126.8, 126.6, 125.7, 125.3, 122.4, 122.0, 120.4, 118.0, 117.9, 116.3, 65.4; Anal. Calcd for C₂₄H₁₇N₃O₂: C, 75.98; H, 4.52; N, 11.08%; Found: C, 75.78; H, 4.57; N, 10.96%.




(E)-3-(2-(2H-indazol-2-yl)phenyl)allyl isonicotinate (3ad): Yellow gummy mass (78%, 69.3 mg); R_f = 0.45 (PE/ EA = 80 : 20); ¹H NMR (400 MHz, CDCl₃): δ 9.16 (d, J = 1.2 Hz, 1H), 8.73-8.72 (m, 1H), 8.12-8.09 (m, 2H), 7.77 (d, J = 9.0 Hz, 1H), 7.73-7.69 (m, 2H), 7.51-7.45 (m, 2H), 7.44-7.41 (m, 1H), 7.36-7.32 (m, 1H), 7.27-7.24 (m, 1H), 7.15-7.12 (m, 1H), 6.53 (d, J = 16.0 Hz, 1H), 6.42-6.35 (m, 1H), 4.90-4.88 (m, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 164.8, 153.3, 150.8, 149.4, 138.9, 137.0, 132.1, 129.3, 128.7, 128.6, 126.9, 126.8, 126.0, 125.3, 123.3, 122.4, 122.0, 120.4, 117.8, 65.4; Anal. Calcd for C₂₂H₁₇N₃O₂: C, 74.35; H, 4.82; N, 11.82%; Found: C, 74.51; H, 4.78; N, 11.90%.




(E)-3-(2-(2H-indazol-2-yl)phenyl)allyl pivalate (3ae): Yellow gummy mass (96%, 80.2 mg); R_f = 0.50 (PE/ EA = 92 : 8); ¹H NMR (400 MHz, CDCl₃): δ 8.10 (s, 1H), 7.79 (d, J = 8.4 Hz, 1H), 7.73-7.67 (m, 2H), 7.50-7.31 (m, 4H), 7.15-7.11 (m, 1H), 6.39 (d, J = 16.0 Hz, 1H), 6.32-6.25 (m, 1H), 4.63-4.61 (m, 2H), 1.05 (s, 9H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 178.0, 149.5, 138.9, 132.4, 129.3, 128.4, 127.0, 126.9, 126.7, 126.67, 126.62, 125.3, 122.3,


122.1, 120.3, 117.9, 64.0, 38.7, 27.0; Anal. Calcd for C₂₁H₂₂N₂O₂: C, 75.42; H, 6.63; N, 8.38%; Found: C, 75.61; H, 6.60; N, 8.44%.




(E)-3-(2-(2H-indazol-2-yl)phenyl)allyl cyclohexanecarboxylate (3af): Yellow gummy mass (94%, 84.6 mg); R_f = 0.50 (PE/ EA = 90 : 10); ¹H NMR (400 MHz, CDCl₃): δ 8.10 (s, 1H), 7.81-7.78 (m, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.69-7.67 (m, 1H), 7.50-7.32 (m, 4H), 7.16-7.12 (m, 1H), 6.38 (d, J = 16.0 Hz, 1H), 6.31-6.25 (m, 1H), 4.63-4.62 (m, 2H), 2.22-2.14 (m, 1H), 1.77-1.73 (m, 1H), 1.64-1.54 (m, 3H), 1.31-1.22 (m, 3H), 1.18-1.10 (m, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 175.6, 149.4, 138.8, 132.3, 129.2, 128.4, 127.0, 126.9, 126.7, 125.3, 122.3, 122.0, 120.4, 117.9, 63.9, 43.1, 28.9, 25.6, 25.4; Anal. Calcd for C₂₃H₂₄N₂O₂: C, 76.64; H, 6.71; N, 7.77%; Found: C, 76.87; H, 6.75; N, 7.68%.




(E)-3-(2-(2H-indazol-2-yl)phenyl)allyl (3r,5r,7r)-adamantane-1-carboxylate (3ag): Yellow solid (89%, 91.7 mg); R_f = 0.50 (PE/ EA = 90 : 10); M.P. 87-88 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.10 (s, 1H), 7.79 (d, J = 9.2 Hz, 1H), 7.74-7.67 (m, 2H), 7.50-7.38 (m, 3H), 7.35-7.31 (m, 1H), 7.13 (t, J = 8.4 Hz, 1H), 6.37 (d, J = 14.4 Hz, 1H), 6.32-6.25 (m, 1H), 4.64-4.63 (m, 2H), 1.90-1.86 (m, 3H), 1.70 (d, J = 2.4 Hz, 6H), 1.63 (d, J = 12.4 Hz, 3H), 1.53 (d, J = 11.6 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 177.2, 149.5, 138.9, 132.5, 129.3, 128.4, 127.2, 126.9, 126.7, 126.6, 126.2, 125.4, 122.4, 122.1, 120.4, 117.9, 63.6, 40.7, 38.7, 36.4, 27.8; Anal. Calcd for C₂₇H₂₈N₂O₂: C, 78.61; H, 6.84; N, 6.79%; Found: C, 78.44; H, 6.86; N, 6.89%.




(E)-5-(2-(2H-indazol-2-yl)phenyl)pent-4-en-1-yl benzoate (3ah): Yellow gummy mass (49%, 46.8 mg); R_f = 0.45 (PE/ EA = 90 : 10); ¹H NMR (400 MHz, CDCl₃): δ 8.11 (s, 1H), 8.00-7.97 (m, 2H), 7.80 (d, J = 8.4 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.48-7.45 (m, 2H), 7.43-7.33 (m, 4H), 7.12 (t, J = 8.0 Hz, 1H), 6.30-6.23 (m, 1H), 6.19 (d, J = 15.6 Hz, 1H), 4.31 (t, J = 6.4 Hz, 2H), 2.31-2.26 (m, 2H), 1.90-1.83 (m, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 166.7, 149.4, 138.5, 133.6, 133.1, 133.0, 130.3, 129.6, 129.3, 128.4, 127.7, 127.0, 126.7, 126.6, 125.6, 125.3, 122.3, 122.1, 120.5, 118.0, 64.3, 29.7, 28.3; Anal. Calcd for C₂₅H₂₂N₂O₂: C, 78.51; H, 5.80; N, 7.32%; Found: C, 78.38; H, 5.76; N, 7.25%.




(E)-2-(2-(3-(p-tolyloxy)prop-1-en-1-yl)phenyl)-2H-indazole (3ai): Yellow gummy mass (95%, 80.8 mg); $R_f = 0.50$ (PE/ EA = 90 : 10); ^1H NMR (400 MHz, CDCl_3): δ 8.07 (s, 1H), 7.85 (d, $J = 8.8$ Hz, 1H), 7.73 (d, $J = 8.0$ Hz, 2H), 7.53 (d, $J = 7.6$ Hz, 1H), 7.49-7.37 (m, 3H), 7.18 (t, $J = 7.6$ Hz, 1H), 7.07 (d, $J = 8.4$ Hz, 2H), 6.77 (d, $J = 8.4$ Hz, 2H), 6.54 (d, $J = 16.0$ Hz, 1H), 6.47-6.42 (m, 1H), 4.58 (d, $J = 5.6$ Hz, 2H), 2.30 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 156.2, 149.4, 138.8, 132.3, 130.1, 129.9, 129.2, 128.45, 128.41, 127.5, 126.9, 126.8, 126.6, 125.3, 122.3, 122.0, 120.4, 117.9, 114.6, 68.4, 20.5; Anal. Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{O}$: C, 81.15; H, 5.92; N, 8.23%; Found: C, 81.34; H, 5.97; N, 8.31%.



(E)-N-(3-(2-(2H-indazol-2-yl)phenyl)allyl)-4-methylaniline (3aj): Yellow gummy mass (79%, 67.0 mg); $R_f = 0.50$ (PE/ EA = 90 : 10); ^1H NMR (400 MHz, CDCl_3): δ 8.02 (s, 1H), 7.79 (d, $J = 9.2$ Hz, 1H), 7.68-7.66 (m, 2H), 7.51-7.48 (m, 1H), 7.46-7.33 (m, 3H), 7.16-7.12 (m, 1H), 6.95 (d, $J = 8.4$ Hz, 2H), 6.50 (d, $J = 8.4$ Hz, 2H), 6.41 (d, $J = 16.0$ Hz, 1H), 6.35-6.29 (m, 1H), 3.82 (d, $J = 5.2$ Hz, 2H), 2.24 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.5, 145.1, 138.7, 132.8, 130.9, 129.8, 129.2, 128.2, 127.2, 127.0, 126.9, 126.7, 126.4, 125.4, 122.3, 122.1, 120.5, 118.0, 113.5, 46.5, 20.5; Anal. Calcd for $\text{C}_{23}\text{H}_{21}\text{N}_3$: C, 81.38; H, 6.24; N, 12.38%; Found: C, 81.52; H, 6.21; N, 12.27%.




(E)-2-(2-(3-(p-tolylthio)prop-1-en-1-yl)phenyl)-2H-indazole (3ak): Yellow gummy mass (71%, 63.2 mg); $R_f = 0.50$ (PE/ EA = 92 : 8); ^1H NMR (400 MHz, CDCl_3): δ 7.85 (s, 1H), 7.79 (d, $J = 8.8$ Hz, 1H), 7.69 (d, $J = 8.4$ Hz, 1H), 7.64-7.62 (m, 1H), 7.49-7.47 (m, 1H), 7.45-7.41 (m, 1H), 7.39-7.33 (m, 2H), 7.21 (d, $J = 8.0$ Hz, 2H), 7.17-7.13 (m, 1H), 7.06 (d, $J = 8.0$ Hz, 2H), 6.30-6.22 (m, 1H), 6.16 (d, $J = 15.6$ Hz, 1H), 3.53 (d, $J = 7.2$ Hz, 2H), 2.32 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.5, 138.7, 136.9, 132.5, 131.6, 131.4, 129.7, 129.3, 129.2, 128.2, 127.1, 127.0, 126.9, 126.6, 125.3, 122.3, 122.1, 120.4, 118.0, 37.9, 21.2; Anal. Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{S}$: C, 77.49; H, 5.66; N, 7.86%; Found: C, 77.34; H, 5.64; N, 7.76%.




(E)-3-(2-(2H-indazol-2-yl)phenyl)allyl (tert-butoxycarbonyl)-L-phenylalaninate (3al):

Yellow gummy mass (82%, 100.0 mg); $R_f = 0.50$ (PE/ EA = 75 : 25); ^1H NMR (400 MHz, CDCl_3): δ 8.09 (s, 1H), 7.79 (d, $J = 8.4$ Hz, 1H), 7.73 (d, $J = 8.4$ Hz, 1H), 7.69-7.67 (m, 1H), 7.53-7.42 (m, 3H), 7.36-7.32 (m, 1H), 7.24-7.18 (m, 3H), 7.16-7.12 (m, 1H), 7.07-7.05 (m, 2H), 6.44 (d, $J = 16.0$ Hz, 1H), 6.25-6.18 (m, 1H), 4.94 (d, $J = 8.0$ Hz, 1H), 4.66-4.63 (m, 2H), 4.56-4.51 (m, 1H), 3.05-2.89 (m, 2H), 1.40 (s, 9H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 171.6, 155.1, 149.6, 139.0, 136.0, 132.1, 129.4, 129.3, 129.2, 128.8, 128.5, 127.07, 127.00, 126.9, 126.8, 126.1, 125.4, 122.5, 122.1, 120.4, 118.0, 80.0, 65.6, 54.5, 38.3, 28.3; Anal. Calcd for $\text{C}_{30}\text{H}_{31}\text{N}_3\text{O}_4$: C, 72.41; H, 6.28; N, 8.44%; Found: C, 72.57; H, 6.24; N, 8.56%.




(E)-3-(2-(2H-indazol-2-yl)phenyl)allyl (tert-butoxycarbonyl)-L-valinate (3am): Yellow

gummy mass (77%, 86.5 mg); $R_f = 0.50$ (PE/ EA = 80 : 20); ^1H NMR (400 MHz, CDCl_3): δ 8.10 (s, 1H), 7.80-7.77 (m, 1H), 7.73 (d, $J = 8.8$ Hz, 1H), 7.68-7.66 (m, 1H), 7.50-7.40 (m, 3H), 7.36-7.32 (m, 1H), 7.16-7.12 (m, 1H), 6.45 (d, $J = 15.6$ Hz, 1H), 6.31-6.24 (m, 1H), 4.99 (d, $J = 8.8$ Hz, 1H), 4.72-4.61 (m, 2H), 4.18-4.15 (m, 1H), 2.05-1.97 (m, 1H), 1.41 (s, 9H), 0.86 (d, $J = 7.2$ Hz, 3H), 0.76 (d, $J = 6.8$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 172.1, 155.7, 149.5, 138.9, 132.1, 129.3, 128.8, 128.7, 126.9, 126.8, 126.7, 126.1, 125.3, 122.4, 122.1, 120.4, 117.9, 79.7, 65.2, 58.5, 31.2, 28.3, 19.0, 17.4; Anal. Calcd for $\text{C}_{26}\text{H}_{31}\text{N}_3\text{O}_4$: C, 69.47; H, 6.95; N, 9.35%; Found: C, 69.27; H, 6.97; N, 9.27%.




(E)-2-(3-(2-(2H-indazol-2-yl)phenyl)allyl)-1-(tert-butyl)-(S)-indoline-1,2-dicarboxylate


(3an): Yellow gummy mass (72%, 89.1 mg); $R_f = 0.50$ (PE/ EA = 75 : 25); ^1H NMR (400 MHz, CDCl_3): δ 8.10 (s, 1H), 7.89-7.66 (m, 4H), 7.51-7.41 (m, 3H), 7.36 (t, $J = 8.4$ Hz, 1H), 7.19-7.13 (m, 2H), 7.02 (d, $J = 7.2$ Hz, 1H), 6.91 (t, $J = 7.2$ Hz, 1H), 6.45 (d, $J = 16.0$ Hz, 1H), 6.32-6.25 (m, 1H), 4.87-4.73 (m, 2H), 4.68-4.64 (m, 1H), 3.38-3.31 (m, 1H), 2.99-2.94 (m, 1H), 1.45 (s, 9H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 171.5, 151.5, 149.4, 142.4, 138.9, 131.9, 129.2, 128.9, 128.7, 127.8, 126.8, 126.7, 126.3, 125.9, 125.3, 124.7, 124.3, 122.5, 122.4, 122.1, 120.4, 117.8, 114.5, 81.2, 65.3, 60.2, 32.5, 28.2; Anal. Calcd for $\text{C}_{30}\text{H}_{29}\text{N}_3\text{O}_4$: C, 72.71; H, 5.90; N, 8.48%; Found: C, 72.57; H, 5.93; N, 8.54%.



(8R,9S,13S,14S,17R)-17-((E)-2-(2H-indazol-2-yl)styryl)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol (3ao): White solid (68%, 83.3 mg); $R_f = 0.45$ (PE/ EA = 70 : 30), M.P. 109-110 °C; ^1H NMR (400 MHz, DMSO-d₆): δ 9.03 (s, 1H), 8.53 (s, 1H), 7.76 (t, J = 8.8 Hz, 2H), 7.68 (d, J = 8.8 Hz, 1H), 7.56-7.48 (m, 2H), 7.43 (t, J = 8.0 Hz, 1H), 7.30 (t, J = 8.4 Hz, 1H), 7.09 (t, J = 7.6 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 6.50-6.48 (m, 1H), 6.43 (s, 1H), 6.32 (d, J = 16.0 Hz, 1H), 6.21 (d, J = 16.0 Hz, 1H), 4.65 (s, 1H), 2.66 (d, J = 4.4 Hz, 2H), 2.50 (s, 1H), 2.12 (d, J = 8.8 Hz, 1H), 1.91 (s, 2H), 1.71-1.62 (m, 3H), 1.44 (d, J = 9.2 Hz, 1H), 1.25-1.17 (m, 4H), 1.13-1.06 (m, 1H), 0.75 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, DMSO-d₆): δ 154.9, 148.6, 140.5, 138.4, 137.2, 133.6, 130.5, 129.5, 127.6, 127.19, 127.13, 126.3, 126.2, 126.0, 121.8, 121.0, 120.8, 117.4, 114.9, 112.7, 82.8, 48.3, 47.1, 43.1, 36.1, 32.1, 29.2, 27.0, 26.1, 22.8, 21.1, 14.2; Anal. Calcd for C₃₃H₃₄N₂O₂: C, 80.78; H, 6.99; N, 5.71%; Found: C, 80.95; H, 6.94; N, 5.80%.




(8R,9S,10R,13S,14S,17R)-17-((E)-2-(2H-indazol-2-yl)styryl)-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one (3ap): White solid (60%, 73.8 mg); $R_f = 0.50$ (PE/ EA = 70 : 30); M.P. 115-116 °C; ^1H NMR (400 MHz, DMSO-d₆): δ 8.54 (s, 1H), 7.74-7.71 (m, 2H), 7.66 (d, J = 8.8 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.49-7.41 (m, 2H), 7.29 (t, J = 8.4 Hz, 1H), 7.08 (t, J = 8.0 Hz, 1H), 6.25 (d, J = 16.0 Hz, 1H), 6.17 (d, J = 16.0 Hz, 1H), 5.74 (s, 1H), 4.61 (s, 1H), 2.48 (d, J = 14.4 Hz, 1H), 2.21-2.06 (m, 5H), 1.72-1.58 (m, 4H), 1.47-1.33 (m, 3H), 1.29-1.22 (m, 3H), 1.08-0.98 (m, 2H), 0.86-0.82 (m, 1H), 0.78 (s, 3H), 0.65-0.57 (m, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, DMSO-d₆): δ 198.5, 167.0, 148.5, 140.6, 138.3, 133.5, 129.5, 127.5, 127.16, 127.11, 126.3, 126.1, 123.6, 121.75, 121.71, 121.0, 120.8, 117.3, 82.7, 59.7, 48.5, 48.0, 46.8, 41.6, 36.1, 36.0, 34.7, 31.8, 30.2, 26.0, 25.6, 22.9, 14.1; Anal. Calcd for C₃₃H₃₆N₂O₂: C, 80.45; H, 7.37; N, 5.69%; Found: C, 80.22; H, 7.41; N, 5.62%.




(E)-2-(2-(Oct-1-en-1-yl)phenyl)-2H-indazole (3aq): Yellow gummy mass (57%, 43.3 mg); $R_f = 0.55$ (PE/ EA = 97 : 3); ^1H NMR (400 MHz, CDCl₃): δ 8.12 (s, 1H), 7.82-7.80 (m, 1H),


7.74 (d, $J = 8.4$ Hz, 1H), 7.66-7.64 (m, 1H), 7.49-7.46 (m, 1H), 7.45-7.41 (m, 1H), 7.37-7.33 (m, 2H), 7.14 (t, $J = 8.4$ Hz, 1H), 6.26-6.19 (m, 1H), 6.12 (d, $J = 16.0$ Hz, 1H), 2.12-2.07 (m, 2H), 1.40-1.35 (m, 2H), 1.33-1.21 (m, 6H), 0.85 (t, $J = 6.8$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 139.0, 138.4, 135.1, 134.0, 129.2, 127.4, 127.0, 126.7, 126.6, 125.3, 124.6, 122.3, 122.1, 120.4, 118.1, 33.2, 31.8, 29.2, 28.9, 22.7, 14.2; Anal. Calcd for $\text{C}_{21}\text{H}_{24}\text{N}_2$: C, 82.85; H, 7.95; N, 9.20%; Found: C, 82.70; H, 8.00; N, 9.30%.



(E)-2-(2-Styrylphenyl)-2H-indazole (3ar): Yellow gummy mass (75%, 55.5 mg); $R_f = 0.50$ (PE / EA = 96 : 4); ^1H NMR (400 MHz, CDCl_3): δ 8.17 (s, 1H), 7.84 (d, $J = 8.4$ Hz, 2H), 7.74 (d, $J = 8.4$ Hz, 1H), 7.57-7.55 (m, 1H), 7.53-7.49 (m, 1H), 7.45-7.37 (m, 2H), 7.34 (d, $J = 8.4$ Hz, 2H), 7.30-7.28 (m, 2H), 7.25-7.21 (m, 1H), 7.18-7.08 (m, 2H), 6.91 (d, $J = 16$ Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.6, 139.1, 136.9, 133.3, 132.0, 129.3, 128.8, 128.26, 128.22, 127.1, 126.9, 126.78, 126.72, 125.5, 123.4, 122.4, 122.2, 120.5, 118.1 ; Anal. Calcd for $\text{C}_{21}\text{H}_{16}\text{N}_2$: C, 85.11; H, 5.44; N, 9.45%; Found: C, 85.25; H, 5.41; N, 9.34%.




(E)-2-(2-(4-Methylstyryl)phenyl)-2H-indazole (3as): Yellow gummy mass (72%, 55.8 mg); $R_f = 0.50$ (PE / EA = 95 : 5); ^1H NMR (400 MHz, CDCl_3): δ 8.07 (s, 1H), 7.75-7.72 (m, 2H), 7.63 (d, $J = 8.4$ Hz, 1H), 7.47-7.45 (m, 1H), 7.40 (t, $J = 7.2$ Hz, 1H), 7.33-7.28 (m, 2H), 7.15 (t, $J = 8$ Hz, 2H), 7.08-7.04 (m, 1H), 7.00 (t, $J = 8.8$ Hz, 3H), 6.75 (d, $J = 16.4$ Hz, 1H), 2.22 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.6, 139.0, 138.2, 134.1, 133.4, 132.0, 129.5, 129.3, 128.0, 127.0, 126.8, 126.7, 126.6, 125.5, 122.4, 122.3, 122.2, 120.5, 118.1, 21.3; Anal. Calcd for $\text{C}_{22}\text{H}_{18}\text{N}_2$: C, 85.13; H, 5.85; N, 9.03%; Found: C, 85.29; H, 5.81; N, 8.91%.




(E)-2-(2-(4-Methoxystyryl)phenyl)-2H-indazole (3at): Yellow gummy mass (61%, 49.7 mg); $R_f = 0.50$ (PE : EA = 92 : 8); ^1H NMR (400 MHz, CDCl_3): δ 8.17 (s, 1H), 7.85-7.81 (m, 2H), 7.74 (d, $J = 8.4$ Hz, 1H), 7.55-7.53 (m, 1H), 7.51-7.47 (m, 1H), 7.42-7.35 (m, 2H), 7.29 (t, $J = 4.4$ Hz, 2H), 7.18-7.14 (m, 1H), 7.07 (d, $J = 16.0$ Hz, 1H), 6.81 (d, $J = 8.4$ Hz, 2H), 6.75 (d, $J = 16.4$ Hz, 1H), 3.78 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 138.8, 133.6, 131.5, 129.7, 129.3, 128.2, 127.8, 127.1, 126.7, 126.49, 126.44, 125.6, 125.5, 122.3, 122.1,


121.1, 120.5, 118.1, 114.1, 55.4; Anal. Calcd for C₂₂H₁₈N₂O: C, 80.96; H, 5.56; N, 8.58%; Found: C, 80.81; H, 5.52; N, 8.51%.




(E)-2-(2-(4-fluorostyryl)phenyl)-2H-indazole (3au): Yellow gummy mass (87%, 68.3 mg); R_f = 0.50 (PE : EA = 95 : 5); ¹H NMR (400 MHz, CDCl₃): δ 8.16 (s, 1H), 7.86-7.81 (m, 2H), 7.75 (d, J = 8.8 Hz, 1H), 7.56-7.48 (m, 2H), 7.44-7.36 (m, 2H), 7.31-7.28 (m, 2H), 7.19-7.15 (m, 1H), 7.07 (d, J = 16.4 Hz, 1H), 6.99-6.94 (m, 2H), 6.83 (d, J = 16.4 Hz, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 162.6 (C-F, ¹J_{C-F} = 246.0 Hz), 149.6, 139.0, 133.1 (C-F, ³J_{C-F} = 8.0 Hz), 133.0, 130.7, 129.3, 128.4 (C-F, ³J_{C-F} = 8.0 Hz), 128.2, 127.0, 126.6 (C-F, ²J_{C-F} = 24.0 Hz), 125.4, 123.16, 123.14, 122.4, 122.2, 120.5, 118.0, 115.7 (C-F, ²J_{C-F} = 22.0 Hz); Anal. Calcd for C₂₁H₁₅FN₂: C, 80.24; H, 4.81; N, 8.91%; Found: C, 80.41; H, 4.84; N, 9.03%.




(E)-2-(2-(2-(6-Methoxynaphthalen-2-yl)vinyl)phenyl)-2H-indazole (3av): Yellow solid (76%, 71.5 mg); R_f = 0.50 (PE : EA = 93 : 7); M.P. 98-99 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.18 (s, 1H), 7.87-7.84 (m, 2H), 7.73 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 9.2 Hz, 2H), 7.60-7.54 (m, 2H), 7.50 (t, J = 7.6 Hz, 1H), 7.43-7.35 (m, 3H), 7.23 (t, J = 8.0 Hz, 1H), 7.17-7.13 (m, 1H), 7.11-7.05 (m, 2H), 6.70 (d, J = 16.4 Hz, 1H), 3.88 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 158.1, 149.6, 139.0, 134.5, 133.5, 132.5, 132.3, 132.2, 129.7, 129.3, 129.0, 128.4, 128.0, 127.3, 127.2, 127.1, 126.7, 126.6, 125.6, 124.1, 122.6, 122.4, 122.2, 120.6, 119.2, 118.1, 105.9, 55.4 ; Anal. Calcd for C₂₆H₂₀N₂O: C, 82.95; H, 5.36; N, 7.44%; Found: C, 82.74; H, 5.41; N, 7.36%.




(E)-2-(2-(1-Phenylprop-1-en-2-yl)phenyl)-2H-indazole (3aw): Yellow gummy mass (82%, 63.6 mg); R_f = 0.50 (PE/ EA = 95 : 5); ¹H NMR (400 MHz, CDCl₃): δ 8.02 (s, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.49-7.46 (m, 2H), 7.30-7.25 (m, 3H), 7.12 (t, J = 6.8 Hz, 3H), 7.03 (d, J = 7.2 Hz, 3H), 6.92-6.88 (m, 1H), 6.42 (s, 1H), 1.45 (d, J = 1.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 149.3, 141.0, 138.6, 137.5, 136.9, 130.9, 130.0, 129.0, 128.3, 128.2, 128.1, 126.9, 126.8, 126.7, 124.8, 122.5, 122.2, 120.5, 118.0, 18.3; Anal. Calcd for C₂₂H₁₈N₂: C, 85.13; H, 5.85; N, 9.03%; Found: C, 85.27; H, 5.81; N, 8.93%.




(E)-2-(2-(1,2-diphenylvinyl)phenyl)-2H-indazole (3ax): Yellow solid (57%, 55.2 mg); $R_f = 0.50$ (PE : EA = 95 : 5); M.P. 139-140 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.82 (s, 1H), 7.60 (t, $J = 9.6$ Hz, 1H), 7.54-7.45 (m, 4H), 7.19 (t, $J = 8.4$ Hz, 1H), 7.08 (t, $J = 2.4$ Hz, 3H), 7.03-7.00 (m, 2H), 6.97 (t, $J = 7.2$ Hz, 1H), 6.91-6.88 (m, 1H), 6.82-6.76 (m, 5H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.1, 140.8, 140.2, 139.5, 138.3, 137.0, 131.7, 131.0, 129.5, 129.4, 129.1, 128.5, 128.0, 127.5, 127.3, 127.1, 127.0, 126.1, 124.8, 122.0, 121.7, 120.1, 117.7; Anal. Calcd for $\text{C}_{27}\text{H}_{20}\text{N}_2$: C, 87.07; H, 5.41; N, 7.52 %; Found: C, 86.92; H, 5.44; N, 7.64%.



(E)-2-(2-(1,2-diphenylvinyl)-4-methylphenyl)-2H-indazole (3bx): Yellow solid (55%, 53.1 mg); $R_f = 0.50$ (PE : EA = 95 : 5); M.P. 137-138 °C; ^1H NMR (400 MHz, CDCl_3): δ 7.78 (s, 1H), 7.59-7.57 (m, 1H), 7.44 (d, $J = 9.4$ Hz, 1H), 7.39 (d, $J = 8.4$ Hz, 2H), 7.28 (d, $J = 1.6$ Hz, 1H), 7.19-7.15 (m, 1H), 7.09-7.07 (m, 3H), 7.01-6.99 (m, 2H), 6.97-6.93 (m, 1H), 6.91-6.87 (m, 1H), 6.82-6.77 (m, 5H), 2.48 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 140.5, 140.3, 139.1, 138.4, 137.2, 137.1, 132.2, 130.9, 129.5, 129.2, 129.1, 128.0, 127.8, 127.5, 127.1, 127.0, 126.9, 126.0, 124.9, 122.0, 121.6, 120.1, 117.7, 21.3; Anal. Calcd for $\text{C}_{28}\text{H}_{22}\text{N}_2$: C, 87.01; H, 5.74; N, 7.25%; Found: C, 87.14; H, 5.72; N, 7.14%.




(E)-2-(2-(2-(thiophen-3-yl)vinyl)phenyl)-2H-indazole (3ay): Yellow gummy mass (76%, 57.3 mg); $R_f = 0.50$ (PE : EA = 95 : 5); ^1H NMR (400 MHz, CDCl_3): δ 8.16 (s, 1H), 7.86 (d, $J = 8.8$ Hz, 1H), 7.79 (d, $J = 7.6$ Hz, 1H), 7.74 (d, $J = 8.4$ Hz, 1H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.51-7.47 (m, 1H), 7.43-7.36 (m, 2H), 7.21-7.11 (m, 4H), 7.07 (t, $J = 3.6$ Hz, 1H), 6.75 (d, $J = 16.0$ Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.5, 139.7, 138.8, 133.2, 129.2, 128.0, 127.0, 126.7, 126.3, 125.9, 125.4, 125.0, 123.4, 123.2, 122.3, 122.1, 120.5, 118.0; Anal. Calcd for $\text{C}_{19}\text{H}_{14}\text{N}_2\text{S}$: C, 75.47; H, 4.67; N, 9.26%; Found: C, 75.28; H, 4.62; N, 9.33%.




(E)-2-(4-Methyl-2-styrylphenyl)-2H-indazole (3br): Yellow solid (78%, 60.5 mg); $R_f = 0.50$ (PE / EA = 95 : 5); M.P. 108-109 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.02 (s, 1H), 7.72 (d, J


= 9.2 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.53 (s, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.27-7.22 (m, 3H), 7.18-7.11 (m, 4H), 7.06-6.97 (m, 2H), 6.77 (d, J = 16.0 Hz, 1H), 2.38 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.5, 139.2, 136.99, 136.90, 132.9, 131.7, 129.0, 128.7, 128.1, 127.0, 126.8, 126.6, 125.5, 123.5, 122.3, 122.1, 120.5, 118.0, 21.4; Anal. Calcd for $\text{C}_{22}\text{H}_{18}\text{N}_2$: C, 85.13; H, 5.85; N, 9.03%; Found: C, 84.96; H, 5.90; N, 9.15%.




(E)-2-(4-fluoro-2-styrylphenyl)-2H-indazole (3cr): Yellow gummy mass (80%, 62.8 mg); R_f = 0.45 (PE / EA = 95 : 5); ^1H NMR (400 MHz, CDCl_3): δ 8.13 (s, 1H), 7.82 (d, J = 8.4 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.54-7.50 (m, 2H), 7.40-7.36 (m, 1H), 7.33-7.28 (m, 3H), 7.26-7.24 (m, 2H), 7.19-7.15 (m, 1H), 7.14-7.09 (m, 2H), 6.82 (d, J = 16 Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 162.9 (C-F, $^1J_{\text{C-F}} = 247.0$ Hz), 149.7, 136.4, 135.7, 135.6, 135.3, 133.2, 129.06 (C-F, $^3J_{\text{C-F}} = 9.0$ Hz), 128.8, 128.6, 127.0, 126.9, 125.6, 122.5, 122.3 (C-F, $^3J_{\text{C-F}} = 7.0$ Hz), 120.5, 118.1, 115.1 (C-F, $^2J_{\text{C-F}} = 23.0$ Hz), 112.8 (C-F, $^2J_{\text{C-F}} = 24.0$ Hz); Anal. Calcd for $\text{C}_{21}\text{H}_{15}\text{FN}_2$: C, 80.24; H, 4.81; N, 8.91%; Found: C, 80.45; H, 4.83; N, 8.83%.




(E)-2-(4-Chloro-2-styrylphenyl)-2H-indazole (3dr): Yellow solid (58%, 47.9 mg); R_f = 0.50 (PE / EA = 95 : 5); M.P. 101-102 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.14 (s, 1H), 7.83-7.81 (m, 2H), 7.73 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 7.40-7.37 (m, 2H), 7.36-7.33 (m, 2H), 7.31-7.29 (m, 1H), 7.27-7.25 (m, 2H), 7.18-7.16 (m, 1H), 7.11 (d, J = 16 Hz, 1H), 6.84 (d, J = 16.4 Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.8, 137.5, 136.4, 135.2, 134.9, 133.2, 128.8, 128.6, 128.4, 128.1, 127.08, 127.02, 126.5, 125.5, 122.6, 122.36, 122.30, 120.5, 118.1; Anal. Calcd for $\text{C}_{21}\text{H}_{15}\text{ClN}_2$: C, 76.25; H, 4.57; N, 8.47%; Found: C, 76.44; H, 4.53; N, 8.57%.




(E)-2-(4-Bromo-2-styrylphenyl)-2H-indazole (3er): Yellow solid (64%, 60 mg); R_f = 0.50 (PE / EA = 95 : 5); M.P. 140-141 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.10 (s, 1H), 7.93 (d, J = 2.4 Hz, 1H), 7.80-7.78 (m, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.52-7.49 (m, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.36-7.34 (m, 1H), 7.32-7.29 (m, 2H), 7.28-7.26 (m, 1H), 7.24-7.21 (m, 2H), 7.15-7.11 (m, 1H), 7.08 (d, J = 16.4 Hz, 1H), 6.81 (d, J = 16.4 Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.8, 138.0, 136.4, 135.1, 133.3, 131.0, 129.5, 128.8, 128.6, 128.5, 127.08, 127.04, 125.4, 123.3, 122.6, 122.3, 122.2, 120.5, 118.1; HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for $\text{C}_{21}\text{H}_{16}\text{BrN}_2$: 375.0491; found: 375.0497.




Ethyl (E)-4-(2H-Indazol-2-yl)-3-styrylbenzoate (3fr): Yellow solid (73%, 67.2 mg); $R_f = 0.50$ (PE/EA = 92 : 8); M.P. 110-111 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.51 (d, $J = 1.6$ Hz, 1H), 8.21 (s, 1H), 8.09-8.07 (m, 1H), 7.83 (d, $J = 8.4$ Hz, 1H), 7.73 (d, $J = 8.8$ Hz, 1H), 7.67 (d, $J = 8.4$ Hz, 1H), 7.40-7.36 (m, 3H), 7.32-7.27 (m, 3H), 7.24 (d, $J = 12.0$ Hz, 1H), 7.19-7.15 (m, 1H), 6.99 (d, $J = 16.4$ Hz, 1H), 4.49-4.44 (m, 2H), 1.46 (t, $J = 6.8$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.8, 149.9, 142.1, 136.6, 133.1, 131.0, 129.9, 129.0, 128.87, 128.83, 128.5, 128.4, 127.1, 127.0, 125.4, 122.8, 122.7, 122.4, 120.6, 118.1, 61.9, 14.5; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for $\text{C}_{24}\text{H}_{21}\text{N}_2\text{O}_2$: 369.1598; found: 369.1598.



(E)-2-(5-Methyl-2-styrylphenyl)-2H-indazole (3gr): Yellow solid (92%, 71.3 mg); $R_f = 0.50$ (PE / EA = 95 : 5); M.P. 96-97 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.01 (s, 1H), 7.70 (d, $J = 8.8$ Hz, 1H), 7.60-7.57 (m, 2H), 7.23-7.11 (m, 7H), 7.09-7.05 (m, 1H), 7.01 (t, $J = 8.0$ Hz, 1H), 6.95 (d, $J = 16$ Hz, 1H), 6.74 (d, $J = 16.4$ Hz, 1H), 2.29 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.5, 138.9, 138.6, 137.0, 131.1, 130.2, 130.1, 128.7, 128.0, 127.5, 126.79, 126.72, 126.5, 125.5, 123.4, 122.3, 122.1, 120.5, 118.0, 21.1; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for $\text{C}_{22}\text{H}_{19}\text{N}_2$: 311.1543; found: 311.1556.




(E)-2-(5-chloro-2-styrylphenyl)-2H-indazole (3hr): Yellow solid (74%, 61.2 mg); $R_f = 0.50$ (PE / EA = 95 : 5); M.P. 161-162 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.03 (s, 1H), 7.87 (d, $J = 8.4$ Hz, 1H), 7.70-7.68 (m, 2H), 7.62-7.59 (m, 1H), 7.41-7.38 (m, 1H), 7.19 (d, $J = 19.2$ Hz, 5H), 7.05-7.01 (m, 1H), 6.84-6.79 (m, 1H), 6.37-6.32 (m, 1H), 6.26-6.21 (m, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 149.3, 136.8, 136.5, 135.6, 135.0, 134.6, 133.0, 132.7, 131.3, 128.7, 128.5, 128.2, 126.9, 126.6, 126.5, 124.8, 122.5, 122.0, 120.6, 118.2; Anal. Calcd for $\text{C}_{21}\text{H}_{15}\text{ClN}_2$: C, 76.25; H, 4.57; N, 8.47%; Found: C, 76.13; H, 4.59; N, 8.54%.




(E)-5-Fluoro-2-(2-styrylphenyl)-2H-indazole (3ir): Yellow gummy mass (62%, 48.7 mg); $R_f = 0.50$ (PE / EA = 95 : 5); ^1H NMR (400 MHz, CDCl_3): δ 8.11 (s, 1H), 7.83-7.78 (m, 2H), 7.53-7.48 (m, 2H), 7.41 (t, $J = 7.6$ Hz, 1H), 7.33-7.27 (m, 4H), 7.24-7.13 (m, 3H), 7.09 (d, J


= 16.4 Hz, 1H), 6.85 (d, J = 16.4 Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 158.7 (C-F, $^1\text{J}_{\text{C-F}}$ = 239.0 Hz), 147.1, 138.9, 136.8, 133.3, 132.2, 129.5, 128.8, 128.2, 126.99, 126.91, 126.7, 125.6 (C-F, $^3\text{J}_{\text{C-F}}$ = 9.0 Hz), 123.2, 121.5, 121.4, 120.2 (C-F, $^3\text{J}_{\text{C-F}}$ = 10.0 Hz), 118.4 (C-F, $^2\text{J}_{\text{C-F}}$ = 28.0 Hz), 102.8 (C-F, $^2\text{J}_{\text{C-F}}$ = 25.0 Hz); Anal. Calcd for $\text{C}_{21}\text{H}_{15}\text{FN}_2$: C, 80.24; H, 4.81; N, 8.91%; Found: C, 80.38; H, 4.78; N, 8.82%.




(E)-5-fluoro-2-(4-methyl-2-styrylphenyl)-2H-indazole (3jr): Yellow gummy mass (76%, 62.3 mg); R_f = 0.50 (PE : EA = 95 : 5); ^1H NMR (400 MHz, CDCl_3): δ 7.95 (s, 1H), 7.68-7.65 (m, 1H), 7.50 (s, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.21-7.18 (m, 2H), 7.17-7.13 (m, 3H), 7.11-7.07 (m, 2H), 7.05-7.00 (m, 1H), 6.95 (d, J = 16.4 Hz, 1H), 6.71 (d, J = 16.4 Hz, 1H), 2.35 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 158.6 (C-F, $^1\text{J}_{\text{C-F}}$ = 238.0 Hz), 147.0, 139.4, 136.9, 136.7, 132.9, 131.8, 129.0, 128.7, 128.1, 127.0, 126.8, 125.6 (C-F, $^3\text{J}_{\text{C-F}}$ = 8.0 Hz), 123.3, 121.4, 121.3, 120.1 (C-F, $^3\text{J}_{\text{C-F}}$ = 10.0 Hz), 118.2 (C-F, $^2\text{J}_{\text{C-F}}$ = 29.0 Hz), 102.8 (C-F, $^2\text{J}_{\text{C-F}}$ = 24.0 Hz), 21.4; Anal. Calcd for $\text{C}_{22}\text{H}_{17}\text{FN}_2$: C, 80.47; H, 5.22; N, 8.53%; Found: C, 80.29; H, 5.27; N, 8.42%.




(E)-5-chloro-2-(2-styrylphenyl)-2H-indazole (3kr): Yellow gummy mass (52%, 43.2 mg); R_f = 0.50 (PE / EA = 95 : 5); ^1H NMR (400 MHz, CDCl_3): δ 8.11 (s, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.77 (d, J = 9.2 Hz, 1H), 7.71 (d, J = 1.2 Hz, 1H), 7.55-7.50 (m, 2H), 7.45-7.41 (m, 1H), 7.34-7.23 (m, 6H), 7.11 (d, J = 16.0 Hz, 1H), 6.84 (d, J = 16.0 Hz, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 148.0, 138.8, 136.8, 133.3, 132.3, 129.6, 128.8, 128.35, 128.32, 128.2, 128.1, 127.0, 126.9, 126.8, 125.1, 123.1, 122.5, 119.7, 119.2; Anal. Calcd for $\text{C}_{21}\text{H}_{15}\text{ClN}_2$: C, 76.25; H, 4.57; N, 8.47%; Found: C, 76.05; H, 4.54; N, 8.55%.




(E)-5-Chloro-2-(4-methyl-2-styrylphenyl)-2H-indazole (3lr): Yellow solid (79%, 68.1 mg); R_f = 0.50 (PE : EA = 95 : 5); M.P. 104-105 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.06 (s, 1H), 7.75 (d, J = 8.8 Hz, 1H), 7.68 (d, J = 1.2 Hz, 1H), 7.62 (s, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.32-7.27 (m, 5H), 7.24-7.21 (m, 2H), 7.08 (d, J = 16.4 Hz, 1H), 6.80 (d, J = 16.0 Hz, 1H), 2.47 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 147.8, 139.5, 136.8, 136.5, 132.8, 131.9, 129.0, 128.8, 128.2, 128.0, 127.9, 127.0, 126.8, 126.7, 125.1, 123.2, 122.5, 119.6, 119.1, 21.5; Anal. Calcd for $\text{C}_{22}\text{H}_{17}\text{ClN}_2$: C, 76.63; H, 4.97; N, 8.12%; Found: C, 76.76; H, 4.99; N 8.21%.



(E)-2-(4-Chloro-5-fluoro-2-styrylphenyl)-2H-indazole (3mr): Yellow solid (79%, 68.8 mg); R_f = 0.50 (PE : EA = 94 : 6); M.P. 131-132 °C; ¹H NMR (400 MHz, CDCl₃): δ 8.23 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.65-7.62 (m, 1H), 7.51 (t, J = 8.8 Hz, 1H), 7.41-7.34 (m, 4H), 7.30-7.28 (m, 3H), 7.08 (d, J = 16.8 Hz, 1H), 6.51 (d, J = 20.4 Hz, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 158.7 (C-F, ¹J_{C-F} = 249.0 Hz), 149.4, 137.1, 136.3, 136.03, 136.00, 134.9, 128.7 (C-F, ³J_{C-F} = 4.0 Hz), 127.1 (C-F, ³J_{C-F} = 10.0 Hz), 126.8, 125.5, 122.4 (C-F, ²J_{C-F} = 29.0 Hz), 121.6, 120.5, 119.86, 119.84, 117.9, 114.8 (C-F, ²J_{C-F} = 23.0 Hz); HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₂₁H₁₅ClFN₂: 349.0902; found: 349.0908.



(E)-3-(2-(pyridin-2-yl)phenyl)allyl (tert-butoxycarbonyl)-L-phenylalaninate (3nl): Yellow gummy mass (86%, 98.5 mg); R_f = 0.50 (PE/ EA = 80 : 20); ¹H NMR (400 MHz, CDCl₃): δ 8.78 (s, 1H), 7.81 (t, J = 7.6 Hz, 1H), 7.69-7.66 (m, 1H), 7.58-7.56 (m, 1H), 7.48-7.43 (m, 3H), 7.34-7.24 (m, 4H), 7.17 (d, J = 6.8 Hz, 1H), 6.83 (d, J = 16.4 Hz, 1H), 6.26-6.19 (m, 1H), 5.04 (d, J = 8.0 Hz, 1H), 4.80-4.70 (m, 2H), 4.66-4.61 (m, 1H), 3.18-3.06 (m, 2H), 1.47 (s, 9H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 171.7, 158.6, 149.4, 139.5, 136.4, 136.0, 134.5, 133.4, 130.2, 129.5, 128.7, 128.6, 128.3, 127.1, 126.6, 125.0, 123.9, 122.1, 80.0, 66.0, 54.5, 38.4, 28.4; Anal. Calcd for C₂₈H₃₀N₂O₄: C, 73.34; H, 6.59; N, 6.11%; Found: C, 73.52; H, 6.56; N, 6.03%.





(E)-3-(2-(1H-pyrazol-1-yl)phenyl)allyl (tert-butoxycarbonyl)-L-phenylalaninate (3ol): White solid (88%, 98.4 mg); R_f = 0.50 (PE/ EA = 80 : 20); M.P. 61-62 °C; ¹H NMR (400 MHz, CDCl₃): δ 7.62 (s, 1H), 7.52-7.48 (m, 2H), 7.31-7.26 (m, 3H), 7.15-7.07 (m, 3H), 7.01 (d, J = 6.8 Hz, 2H), 6.40 (d, J = 16.0 Hz, 1H), 6.34 (t, J = 2.0 Hz, 1H), 6.08-6.01 (m, 1H), 4.92 (d, J = 8.0 Hz, 1H), 4.62-4.53 (m, 2H), 4.50-4.45 (m, 1H), 3.02-2.89 (m, 2H), 1.30 (s, 9H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 171.6, 155.1, 140.8, 138.7, 135.9, 131.7, 131.4, 129.6, 129.4, 128.8, 128.5, 128.4, 127.0, 126.9, 126.3, 125.3, 106.7, 79.9, 65.6, 54.5, 38.3, 28.3; Anal. Calcd for C₂₆H₂₉N₃O₄: C, 69.78; H, 6.53; N, 9.39%; Found: C, 69.57; H, 6.57; N, 9.27%.

5. References:

- (1) (a) M. R. Kumar, A. Park, N. Park, S. Lee, *Org. Lett.*, 2011, **13**, 3542-3545; (b) G. Bogonda, H. Y. Kim, K. Oh, *Org. Lett.*, 2018, **20**, 2711-2715. (2) P. W. Skelly, J. Sae-Jew, A. P. Kitos Vasconcelos, J. Tasnim, L. Li, J. A. Raskatov, R. Braslau, *J. Org. Chem.*, 2019, **84**, 13615-13623. (3) S. Das, A. Azim, S. K. Hota, S. P. Panda, S. Murarka, S. De Sarkar, *Chem. Commun.*, 2021, **57**, 13130-13133. (4) R. M. Borzilleri, X. Zheng, R. J. Schmidt, J. A. Johnson, S. -H. Kim, J. D. DiMarco, C. R. Fairchild, J. Z. Gougoutas, F. Y. F. Lee, B. H. Long, G. D. Vite, *J. Am. Chem. Soc.*, 2000, **122**, 8890-8897. (5) A. Maji, S. Guin, S. Feng, A. Dahiya, V. K. Singh, P. Liu, D. Maiti, *Angew. Chem. Int. Ed.*, 2017, **56**, 14903-14907.

6. NMR spectra for the synthesized products






Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 479
PROCNO 1


F2 - Acquisition Parameters
Date 20211208
Time 10.08
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpg30
TD 32768
SOLVENT CDCl₃
NS 220
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 77.59
DW 20.800 usec
DE 6.50 usec
TE 294.6 K
D1 2.0000000 sec
D11 0.0300000 sec
TD0 1


===== CHANNEL f1 ======
SF01 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.0000000 W


===== CHANNEL f2 ======
SF02 400.1516006 MHz
NUC2 1H
CPDPRG[2] waltz16
PCPD2 90.00 usec
PLW2 12.0000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W


F2 - Processing parameters
SI 16384
SF 100.6177888 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40















Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 486
PROCNO 1


F2 - Acquisition Parameters
Date 20211212
Time 9.37
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zpg30
TD 32768
SOLVENT CDCl_3
NS 120
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 26.53
DW 20.800 usec
DE 6.50 usec
TE 290.1 K
D1 2.0000000 sec
D11 0.0300000 sec
TDO 1

===== CHANNEL f1 =====
SF01 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.0000000 W

===== CHANNEL f2 =====
SF02 400.1516006 MHz
NUC2 1H
CPDPG[1]2 waltz16
PCPD2 90.00 usec
PLW2 12.0000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W

F2 - Processing parameters
SI 16384
SF 100.6178004 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40






Current Data Parameters
 NAME Dr. A HAJRA-2021-13C
 EXPNO 481
 PROCNO 1


F2 - Acquisition Parameters
 Date 20211208
 Time 13.18
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgpg30
 TD 32768
 SOLVENT CDCl3
 NS 120
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 23.55
 DW 20.800 usec
 DE 12.50 usec
 TE 297.3 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TDO 1

----- CHANNEL f1 -----
 SFO1 100.6278588 MHz
 NUC1 ¹³C
 P1 8.90 usec
 PLW1 54.00000000 W

----- CHANNEL f2 -----
 SFO2 400.1516006 MHz
 NUC2 ¹H
 CPDPRG[2] waltz16
 PCPDP2 90.00 usec
 PLW1 12.00000000 W
 PLW12 0.3223000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177873 MHz
 WDW EM
 SSB 0 1.00 Hz
 LB 0
 GB 0 1.40
 PC






Current Data Parameters
 NAME Dr. A HAJRA-2021-13C
 EXPNO 497
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20211215
 Time_ 19.53
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zppg30
 TD 32768
 SOLVENT CDCl₃
 NS 160
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 26.53
 DW 20.800 usec
 DE 6.50 usec
 TE 292.6 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TDO 1

===== CHANNEL f1 =====
 SF01 100.6278588 MHz
 NUC1 ¹³C
 P1 8.90 usec
 PLW1 54.0000000 W


===== CHANNEL f2 =====
 SF02 400.1516006 MHz
 NUC2 ¹H
 CDPDPRG[2 waltz16
 PCPD2 90.00 usec
 PLW2 12.0000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177903 MHz
 WDW EM
 SSB 0 1.00 Hz
 LB 0
 GB 0 1.40
 PC





¹³C NMR: 100 MHz
Solvent: CDCl₃



Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 491
PROCNO 1

```

F2 - Acquisition Parameters
Date_      20211215
Time_      13.99
INSTRUM   spect
PROBHD   5 mm PABBO BB/
PULPROG  zgpg30
TD        32768
SOLVENT    CDC13
NS         160
DS          2
SWH       24038.461 Hz
FIDRES   0.733596 Hz
AQ        0.6815744 sec
RG        20.64
DW        20.800 used
DE        6.50 used
TE        293.0 K
D1        2.0000000 sec
D11       0.03000000 sec
TD0           3

```


===== CHANNEL f1 =====
SFO1 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.0000000 W


```
===== CHANNEL f2 =====
SF02          400.1516000 MHz
NUC2           1H
CPDPRG[2      waltz16
PCPD2         90.000 usec
PLW2          12.0000000 W
PLW12         0.32231000 W
PLW13         0.16212000 W
```

```

F2 - Processing parameters
SI           16384
SF          100.6177917 MHz
WDW           EM
SSB            0
LB             1.00 Hz
GB            0
PC            1.40

```






Current Data Parameters
 NAME Dr. A HAJRA-2021-13C
 EXPNO 485
 PROCNO 1


F2 - Acquisition Parameters
 Date 20211212
 Time 9.22
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgpg30
 TD 32768
 SOLVENT CDCl₃
 NS 120
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 26.53
 DW 20.800 usec
 DE 6.50 usec
 TE 289.7 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TDO 1

===== CHANNEL f1 =====
 SFO1 100.6278588 MHz
 NUC1 13C
 P1 8.90 usec
 PLW1 54.0000000 W

===== CHANNEL f2 =====
 SFO2 400.1516006 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 S1 16384
 SF 100.6177975 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40






Current Data Parameters
 NAME Dr. A HAJRA-2022-13C
 EXPNO 4
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20220103
 Time 17.03
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zpg30
 TD 32768
 SOLVENT CDCl3
 NS 90
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 106.66
 DW 20.800 usec
 DE 6.50 usec
 TE 297.7 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TDO 1


===== CHANNEL f1 =====
 SF01 100.6278588 MHz
 NUC1 13C
 P1 8.90 usec
 PLW1 54.00000000 W


===== CHANNEL f2 =====
 SF02 400.1516006 MHz
 NUC2 1H
 CPDRG[2] waltz16
 FCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6178009 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40










Current Data Parameters
 NAME Dr. A HAJRA-2021-13C
 EXPNO 506
 PROCNO 1


F2 - Acquisition Parameters
 Date 20211226
 Time 13.28
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 FULPROG zpgpg30
 TD 32768
 SOLVENT CDCl₃
 NS 50
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 20.64
 DW 20.800 usec
 DE 6.50 usec
 TE 294.8 K
 D1 2.0000000 sec
 D11 0.0300000 sec
 TDO 1


===== CHANNEL f1 ======
 SF01 100.6278588 MHz
 NUC1 ¹³C
 P1 8.90 usec
 PLW1 54.00000000 W


===== CHANNEL f2 ======
 SF02 400.1516006 MHz
 NUC2 ¹H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177976 MHz
 WDW EM
 SSB 0 1.00 Hz
 LB 0 1.40
 GB 0
 PC










Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 484
PROCNO 1


F2 - Acquisition Parameters
Date_ 2021208
Time 16.33
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zpg30
TD 32768
SOLVENT CDCl₃
NS 120
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 23.55
DW 20.800 usec
DE 6.50 usec
TE 296.5 K
D1 2.0000000 sec
D11 0.03000000 sec
TDO 1


===== CHANNEL f1 =====
SF01 100.6278588 MHz
NUC1 ¹³C
P1 8.90 usec
PLW1 54.00000000 W


===== CHANNEL f2 =====
SF02 400.1516006 MHz
NUC2 ¹H
CPDRG[2] waltz16
FCPD2 90.00 usec
PLW2 12.00000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W

F2 - Processing parameters
SI 16384
SF 100.6177990 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40










Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 438
PROCNO 1


F2 - Acquisition Parameters
Date_ 20211118
Time_ 12.12
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpp30
TD 32768
SOLVENT CDCl₃
NS 220
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 54.07
DW 20.800 usec
DE 6.50 usec
TE 295.6 K
D1 2.0000000 sec
D11 0.0300000 sec
TDO 1


===== CHANNEL f1 =====
SF01 100.6278588 MHz
NUC1 ¹³C
P1 8.90 usec
PLW1 54.00000000 W


===== CHANNEL f2 =====
SF02 400.1516006 MHz
NUC2 ¹H
CPDPRG[2] waltz16
FCPD2 90.00 usec
PLW2 12.00000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W

F2 - Processing parameters
SI 16384
SF 100.6177960 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
FC 1.40









Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 453
PROCNO 1

```

F2 - Acquisition Parameters
Date_      20211126
Time       12.25
INSTRUM   spect
PROBHD   5 mm PABBO BB/
PULPROG  zgpr60
TD        32768
SOLVENT    CDCl3
NS         100
DS          2
SWH       24038.461 Hz
FIDRES   0.733596 Hz
AQ        0.6815744 sec
RG        40.87
DW        20.800 usec
DE        6.50
TE        293.0 K
D1        2.0000000 sec
D11       0.03000000 sec
TE0           1

```


```
===== CHANNEL f1 =====
SFO1      100.6278588 MHz
NUC1      13C
P1        8.90 usec
PLW1      54.0000000 W
```


```
===== CHANNEL f2 =====
SF02          400.1516006 MHz
NUC2           1H
CPDPRG[2]      waltz16
PCPD2          90.00 usec
PLW2           12.0000000 W
PLW12          0.32231000 W
PLW13          0.16212000 W
```


```


F2 - Processing parameters
SI          16384
SF          100.6177961 MHz
WDW         EM
SSB          0
LB           1.00 Hz
GB          0
PC          1.40


```

































Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 449
PROCNO 1


F2 - Acquisition Parameters
Date 20211121
Time 15.49
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpg30
TD 32768
SOLVENT CDCl₃
NS 450
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 168.31
DW 20.800 usec
DE 6.50 usec
TE 296.6 K
D1 2.0000000 sec
D11 0.03000000 sec
TDO 1


===== CHANNEL f1 =====
SF01 100.627858 MHz
NUC1 ¹³C
P1 8.90 usec
PLW1 54.00000000 W


===== CHANNEL f2 =====
SF02 400.1516006 MHz
NUC2 ¹H
CPDPG[2] waltz16
PCPD2 90.00 usec
PLW2 12.00000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W

F2 - Processing parameters
SI 16384
SF 100.6177858 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40










Current Data Parameters
 NAME Dr. A HAJRA-2021-13C
 EXPNO 462
 PROCNO 1


F2 - Acquisition Parameters
 Date 20211128
 Time 18.52
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgpp30
 TD 32768
 SOLVENT CDCl3
 NS 285
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 62.69
 DW 20.800 usec
 DE 6.50 usec
 TE 297.4 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TDO 1

===== CHANNEL f1 =====
 SF01 100.6278588 MHz
 NUC1 13C
 P1 8.90 usec
 PLW1 54.00000000 W

===== CHANNEL f2 =====
 SF02 400.1516006 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177889 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40





Current Data Parameters
 NAME Dr. A HAJRA-2021-13C
 EXPNO 505
 PROCNO 1


F2 - Acquisition Parameters


Date_ 20211226
 Time_ 13.11
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgpg30
 TD 32768
 SOLVENT CDCl₃
 NS 80
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 20.64
 DW 20.800 usec
 DE 6.50 usec
 TE 294.7 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TDO 1


===== CHANNEL f1 =====
 SF01 100.6278588 MHz
 NUC1 ¹³C
 P1 8.90 usec
 PLW1 54.0000000 W


===== CHANNEL f2 =====
 SF02 400.1516006 MHz
 NUC2 ¹H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.0000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W


F2 - Processing parameters
 SI 16384
 SF 100.6177947 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 FC 1.40



























¹³C NMR: 100 MHz
Solvent: CDCl₃

Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 50
PROCNO 1

```

F2 - Acquisition Parameters
Date_      20201026
Time_      21.12
INSTRUM   spect
PROBHD   5 mm PABHD BB/
PULPROG  zgpp30
TD        32768
SOLVENT   CDC13
NS        380
DS        2
SWH      24038.461 Hz
FIDRES   0.733596 Hz
AQ        0.6815744 sec
RG        186.42
DW        20.800 usec
DE        6.50 usec
TE        295.4 K
D1        2.0000000 sec
D11       0.03000000 sec
TD0       1

```


===== CHANNEL f1 =====
SFO1 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.00000000 W


```
===== CHANNEL f2 =====
SFO2          400.1516006 MHz
NUC2           1H
CPDRG[2]      waltz16
PCPD2         90.00 usec
PLW2          12.0000000 W
PLW12         0.32231000 W
PLW13         0.16212000 W
```

```

F2 - Processing parameters
SI           16384
SF          100.6177858 MHz
WDW          EM
SSB          0
LB           1.00 Hz
GB          0
PC          1.40

```






Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 88
PROCNO 1


F2 - Acquisition Parameters
Date_ 20210218
Time 0.44
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgppg30
TD 32768
SOLVENT CDCl₃
NS .512
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 120.16
DW 20.800 usec
DE 6.50 usec
TE 294.5 K
D1 2.0000000 sec
D11 0.03000000 sec
TD0 1

===== CHANNEL f1 =====
SF01 100.6278588 MHz
NUC1 ¹³C
P1 8.90 usec
PLW1 54.0000000 W

===== CHANNEL f2 =====
SF02 400.1516006 MHz
NUC2 ¹H
CPDPG[2] waltz16
PCPD2 90.00 usec
PLW2 12.00000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W

F2 - Processing parameters
SI 16384
SF 100.6177873 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40






Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 63
PROCNO 1



F2 - Acquisition Parameters
Date 20210209
Time 10.34
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpp30
TD 32768
SOLVENT CDCl₃
NS 650
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 168.31
DW 20.800 usec
DE 6.50 usec
TE 290.0 K
D1 2.0000000 sec
D11 0.03000000 sec
TDO 1

===== CHANNEL f1 =====
SF01 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.00000000 W

===== CHANNEL f2 =====
SF02 400.1516006 MHz
NUC2 1H
CPDPG[2] waltz16
PCPD2 90.00 usec
PLW2 12.00000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W

F2 - Processing parameters
SI 16384
SF 100.6177873 MHz
WDW EM
SSB 0 1.00 Hz
LB 0
GB 0
PC 1.40






Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 69
PROCNO 1


F2 - Acquisition Parameters
Date_ 20210209
Time_ 23.49
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpg30
TD 32768
SOLVENT CDCl₃
NS 220
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 57.28
DW 20.800 usec
DE 6.50 usec
TE 293.3 K
D1 2.0000000 sec
D11 0.0300000 sec
TDO 1


===== CHANNEL f1 =====
SF01 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.0000000 W


===== CHANNEL f2 =====
SF02 400.1516006 MHz
NUC2 1H
CPDPRG[2] waltz16
PCPD2 90.00 usec
PLW2 12.00000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W


F2 - Processing parameters
SI 16384
SF 100.6177922 MHz
WDW EM
SSB 0 1.00 Hz
LB 0 1.40
GB 0
PC
















Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 91
PROCNO 1


F2 - Acquisition Parameters
Date 20210218
Time 2.35
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgdc
TD 32768
SOLVENT CDCl₃
NS 320
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 120.16
DW 20.800 usec
DE 6.50 usec
TE 293.6 K
D1 2.0000000 sec
D11 0.03000000 sec
TD0 1

===== CHANNEL f1 =====
SF01 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.00000000 W

===== CHANNEL f2 =====
SF02 400.1516006 MHz
NUC2 1H
CPDPRG[2] waltz16
PCPD2 90.00 usec
PLW2 12.00000000 W
PLW12 0.32231000 W

F2 - Processing parameters
SI 16384
SF 100.6177873 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.00






Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 299
PROCNO 1


F2 - Acquisition Parameters
Date 20210818
Time 19.33
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgdc
TD 32768
SOLVENT CDCl₃
NS 640
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 186.42
DW 20.800 usec
DE 6.50 usec
TE 298.5 K
D1 2.0000000 sec
D11 0.03000000 sec
T00 1


===== CHANNEL f1 ======
SF01 100.6278588 MHz
NUC1 ¹³C
P1 8.90 usec
PLW1 54.0000000 W


===== CHANNEL f2 ======
SF02 400.1516006 MHz
NUC2 ¹H
CPDPRG[2] waltz16
PCPD2 90.00 usec
PLW2 12.0000000 W
PLW12 0.32231000 W


F2 - Processing parameters
SI 16384
SF 100.6177842 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.00















Current Data Parameters
 NAME Dr. A HAJRA-2021-13C
 EXPNO 161
 PROCNO 1


F2 - Acquisition Parameters
 Date 20210324
 Time 3.27
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgdc
 TD 32768
 SOLVENT CDCl₃
 NS 880
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 120.16
 DW 20.800 usec
 DE 6.50 usec
 TE 295.7 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 T0D 1


===== CHANNEL f1 ======SF01 100.6278588 MHz
 NUC1 13C
 P1 8.90 usec
 PLW1 54.00000000 W


===== CHANNEL f2 ======SF02 400.1516006 MHz
 NUC2 1H
 CDPGRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177858 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.00














S110
























































Current Data Parameters
NAME Dr. A HAJRA-2021-13C
EXPNO 473
PROCNO 1

F2 - Acquisition Parameters
Date 20211205
Time 17.34
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpp30
TD 32768
SOLVENT CDCl3
NS 380
DS 2
SWH 24038.461 Hz
FIDRES 0.733596 Hz
AQ 0.6815744 sec
RG 30.11
DW 20.800 usec
DE 6.50 usec
TE 295.7 K
D1 2.0000000 sec
D11 0.03000000 sec
TD0 1

CHANNEL f1
SF01 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.0000000 W

CHANNEL f2
SF02 400.1516006 MHz
NUC2 1H
CPDPRG[2] waltz16
PCPD2 90.00 usec
PLW2 12.00000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W

F2 - Processing parameters
SI 16384
SF 100.6177948 MHz
WDW EM
SSB 0 1.00 Hz
LB 0
GB 0 1.40
PC